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Introduction. Patient-level simulation models facilitate extrapolation of clinical trial data while allowing for heteroge-
neity, prior history, and nonlinearity. However, combining different types of uncertainty around within-trial and
extrapolated results remains challenging. Methods. We tested 4 methods to combine parameter uncertainty (around
the regression coefficients used to predict future events) with sampling uncertainty (uncertainty around mean risk
factors within the finite sample whose outcomes are being predicted and the effect of treatment on these risk factors).
We compared these 4 methods using a simulation study based on an economic evaluation extrapolating the
AFORRD randomized controlled trial using the UK Prospective Diabetes Study Outcomes Model version 2. This
established type 2 diabetes model predicts patient-level health outcomes and costs. Results. The 95% confidence
intervals around life years gained gave 25% coverage when sampling uncertainty was excluded (i.e., 25% of 95%
confidence intervals contained the ‘‘true’’ value). Allowing for sampling uncertainty as well as parameter uncertainty
widened confidence intervals by 6.3-fold and gave 96.3% coverage. Methods adjusting for baseline risk factors that
combine sampling and parameter uncertainty overcame the bias that can result from between-group baseline imbal-
ance and gave confidence intervals around 50% wider than those just considering parameter uncertainty, with
99.8% coverage. Conclusions. Analyses extrapolating data for individual trial participants should include both sam-
pling uncertainty and parameter uncertainty and should adjust for any imbalance in baseline covariates.
Keywords
diabetes, patient-level simulation models, randomized controlled trial, decision-analytical modeling
Date received: July 9, 2019; accepted: February 25, 2020
Decision-analytical models are increasingly used to extra-
polate individual-participant data (IPD) from rando-
mized controlled trials (RCTs). For chronic diseases,
extrapolation is almost unavoidable, as interventions can
take many years before they have a measurable impact
on clinical outcomes. Extrapolation may also be needed
when the primary outcome of a trial is a proxy or inter-
mediate outcome, such as a change in a known risk fac-
tor. It is particularly relevant for economic evaluations,
which generally need to use a lifetime time horizon and
estimate outcomes such as life expectancy or quality-
adjusted life years (QALYs).1 Patient-level simulation
(PLS) models are now in routine use. For example, in the
United Kingdom Prospective Diabetes Study Outcomes
Model version 2 (UKPDS-OM2), patient characteristics
and prior events affect the risk or consequences of subse-
quent events in type 2 diabetes.2,3 Such dependencies are
more difficult to capture in aggregate ‘‘cohort’’ models.
Furthermore, when PLS models are used to extrapolate
IPD, it becomes easier to capture heterogeneity and to
account for the effect of patient history on the risk of
Corresponding Author
Helen Dakin, Nuffield Department of Population Health, Health
Economics Research Centre, University of Oxford, Old Road Campus,
Headington, Oxford, OX3 7LF, UK (helen.dakin@ndph.ox.ac.uk).
subsequent events. By modeling the entire distribution of
risk factors rather than the ‘‘average’’ patient, such mod-
els can also allow for nonlinear effects of patient charac-
teristics on model outcomes and allow for treatment
changes that are based on individual rather than aggre-
gate outcomes.4,5
The increased flexibility offered by PLS models comes
at the expense of greater computational burden and
additional complexity concerning how to handle uncer-
tainty in the resulting estimates of cost-effectiveness or
life expectancy. The reporting of uncertainty is often far
from transparent. For example, although uncertainty in
economic evaluations arises from several different
sources, few published analyses attempt to systematically
decompose the various contributions to overall uncer-
tainty. Several publications have attempted to define
taxonomies for either trial- or model-based economic
evaluations,6–8 but these existing taxonomies do not
explicitly discuss uncertainty arising from missing data
and do not make specific recommendations on how
uncertainty in PLS models should be handled.
Studies that combine IPD and model-based extrapola-
tions are subject to the uncertainties inherent within both
types of analyses. Extrapolating RCT data using a model
requires combining data from 2 distinct time periods:
observed IPD over the within-trial period in which spe-
cific individuals are followed up on assigned interven-
tions and simulated IPD during the modeled posttrial
period in which outcomes depend not only on patient
characteristics but also on model parameters. However,
there has been little research on methods for combining
uncertainty in this context, in contrast to the well-
established methods for combining different types of
uncertainty within multiple imputation.9,10
Our study aims to offer suggestions for improving
analytic methods and reporting standards for PLS-based
extrapolations of trial data by 1) developing and com-
paring methods for combining sampling uncertainty and
parameter uncertainty and 2) assessing the impact of
including stochastic uncertainty. After setting out gen-
eral principles, we compare different methods in a simu-
lation study based on a case study in which the UKPDS-
OM22,3 was used to extrapolate results of an RCT (the
Atorvastatin in a Factorial design with Omega-3 fatty
acids on cardiovascular Risk Reduction in patients with
Type 2 Diabetes study, AFORRD11).
Uncertainty for Studies Extrapolating Trial
Data Using PLS
We combined published taxonomies categorizing the
types of uncertainty affecting model-based6,7 and trial-
based7,8 economic evaluations (Table 1). In this article,
we focus on methods to combine sampling uncertainty
and parameter uncertainty. Parameter uncertainty com-
prises uncertainty around model inputs (e.g., utilities,
costs, and probabilities) and is often handled using prob-
abilistic sensitivity analysis (PSA).1,6,12
Both sampling variation and patient heterogeneity
arise in studies using IPD or in model-based economic
evaluations that extrapolate outcomes for a finite sample
of nonidentical individuals. Trial outcomes will vary
between individual participants by chance: for example,
some patients will have events and others with identical
risk factors will not. Unlike stochastic uncertainty within
a PLS model, we cannot eliminate this chance variation
by running millions of model runs. Some of the variabil-
ity may be explained by patients’ baseline characteristics;
this explainable variation is termed heterogeneity and
could be dealt with using subgroup analysis and/or
regression analyses. However, sampling uncertainty (i.e.,
nonzero standard errors [SEs]) around mean outcomes
will remain even after controlling for all observed base-
line variables, since RCTs use finite samples and do not
provide perfect information. For example, there may be
sampling uncertainty around the mean baseline and
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Table 1 Taxonomy of the Types of Uncertainty Affecting Trial-Based Economic Evaluations and Other Studies Extrapolating
Randomized Controlled Trial Data Using Patient-Level Simulation Models






Perspective, time horizon, discount











Variability in patients’ costs and
outcomes during the randomized
trial period
Statistical analysis: we develop
methods for combining sampling
uncertainty with parameter
uncertainty and adjusting for
baseline characteristics
Subgroup analyses
No variability in life years (no
patients died); individual
patients’ within-trial life years
were added to those in the
extrapolated period
Variability between patients in the
sample
Extrapolated outcomes for each
individual in the trial population
Sampling uncertainty around
mean within-trial treatment
effects (if individual trial
participants are extrapolated, as
randomized)a







effects (if these are explicitly
modeled)a
PSA Not applicable
Uncertainty around costs and
utilities associated with health
states/events
PSA or bootstrapping Not applicable (focus on life
expectancy)




PSA or bootstrapping Used 800 sets of bootstrapped risk
equation parameters
Uncertainty around trajectories of
risk factors beyond the trial
period (if parameterized)a




Report MCE and/or impact of
MCE on results
Run sufficient loops that MCE is
negligible5,17,18
O’Hagan et al.17 present ANOVA-
based methods for eliminating
bias
First set of analyses used sufficient
loops and bootstraps to
minimize MCE.
Second set of analyses assesses the





assumptions about risk factor
trajectories beyond the trial
perioda
Sensitivity analysis Not captured (sensitivity analysis
reported separately)
Uncertainty concerning the
duration of treatment effect
beyond the trial period
Sensitivity analysis Not captured
Selection of the specification of
extrapolation models: functional
form, which variables to include
Scenario analysis, model selection
or averaging, parameterization,
and estimating discrepancies





Sensitivity analysis where practical Not captured






Multinational/multicenter trials Sensitivity analysis Not captured
Applicability to different countries Sensitivity analysis Not captured
External validity of the trial Sensitivity analysis Not captured
(continued)
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posttreatment characteristics of the sample of patients
recruited to the trial and the absolute or incremental
costs, life years, and QALYs accrued during the trial
period; variations between patients at the start of the
simulation will also propagate sampling uncertainty into
estimates of mean costs or life expectancy in the period
extrapolated using the PLS. When calculating SEs
around mean outcomes for a group of patients, we need
to use statistical methods to allow for the fact that the
sample is finite and was sampled from a larger popula-
tion, particularly when estimating differences between
treatments.
Methods for Quantifying and Combining
Parameter and Sampling Uncertainty
When analyzing results, it is necessary to combine differ-
ent forms of uncertainty to produce an overall SE or
95% confidence interval (CI) around estimates of mean
lifetime outcomes.i However, methods to do so are cur-
rently underdeveloped. Several methods could be used to
combine parameter and sampling uncertainty.
Rubin’s rule9,10 is widely used following multiple
imputation of missing data to combine uncertainty
around imputed values with sampling variation from a
trial.13,14 This method involves adding the variance
between imputed data sets to the variance within each
imputation.9,10 PLS models, such as the UKPDS-OM2,
can be viewed as a form of multiple imputation, in which
the model is used to predict or impute missing values for
all participants after the end of the trial, with the model
predictions using M sets of model parameters (sampled
using PSA or bootstrapping) representing M imputa-
tions. On that basis, the original application of UKPDS-
OM version 1 (UKPDS-OM1) adjusted 95% CIs to take
account of the variance within and between different
bootstraps using Rubin’s rule,3,15 although to our knowl-
edge, no such adjustment has been made in any subse-
quent application of UKPDS-OM1 or UKPDS-OM2.
In multiple imputation, it is recommended that
imputed values include random components that take
into account the SEs around the regression coefficients
predicting the missing values (i.e., parameter uncer-
tainty), the residuals from the regression (i.e., stochastic
uncertainty), and the patients’ characteristics (i.e., hetero-
geneity).13,16 In PLS models, stochastic (or first-order)
uncertainty arises because the occurrence of an event
depends on both its probability and chance, via Monte
Carlo methods,6 and is measured using Monte Carlo error
(MCE). If we view the PLS as a ‘‘multiple imputation’’
model, it could be argued that MCE should be included to
mirror the lifetime trial data that are ‘‘missing.’’ However,
in general, it is recommended that PLS models eliminate
MCE by running large numbers of Monte Carlo trials and
averaging the results to produce consistent outcomes5,6,17,18:
otherwise, MCE will bias and inflate SEs.17 This approach
views stochastic uncertainty as random noise resulting from
the computer simulation, rather than genuine uncertainty
around the evidence or methods.
Alternative approaches can also be used to combine
parameter and sampling uncertainty. In the variance
sum law, uncertainty around 2 random variables is com-
bined by summing the variances (minus any covariance)
to calculate the variance around the sum or difference
Table 1 (continued)




7) Imputation uncertainty Uncertainty around the true value
for missing data that should
have been collected within the




Sensitivity analysis on imputation
methods13,14
Not captured (complete case
analysis)
Uncertainty around the true value
for patients after they were
administratively or informatively






Sensitivity analysis on methods
Not relevant to the 16-week trial
AFORRD, Atorvastatin in a Factorial design with Omega-3 fatty acids on cardiovascular Risk Reduction in patients with Type 2 Diabetes
study; ANOVA, analysis of variance; MCE, Monte Carlo error; PSA, probabilistic sensitivity analysis; SE, standard error; UKPDS-OM2,
United Kingdom Prospective Diabetes Study Outcomes Model version 2.
aThese subtypes of uncertainty appear in the table twice as they could fall into 1 of 2 categories depending on the methods used.
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between the variables. Similarly, analysis of variance
(ANOVA) partitions variances into different factors that
can be summed together.19 Nonparametric techniques,
such as bootstrapping, can also be used to combine
uncertainty around correlated endpoints.3,8 Parametric
methods such as PSA8 or Markov chain Monte Carlo20
may also be used to synthesize data from different
sources and quantify uncertainty, although these are out-
side the scope of the current study since they cannot eas-
ily be applied to the way that we extrapolated trial data
using the UKPDS-OM2.
There may also be chance differences in baseline char-
acteristics between randomized groups. It is well estab-
lished that baseline imbalance in EQ-5D utility biases
estimates of incremental QALYs, since baseline utility is
directly included in the estimates of QALYs for each
patient.21 However, to our knowledge, it has not previ-
ously been recognized that the same is true for baseline
imbalance in the risk factors used to extrapolate IPD
within PLS models like the UKPDS-OM2. For example,
if the patients in the control arm of an RCT are older
than in the treatment group, this chance difference will
increase event rates and decrease life expectancy and
QALYs within the control arm as event rates and mortal-
ity increase with age in the model; unless we adjusted for
this baseline imbalance, we would therefore overestimate
the benefits of treatment. Appendix 1 gives a worked
example illustrating this bias. In practice, it is unlikely
that any RCT will be perfectly balanced for all 17 risk
factors in UKPDS-OM2, and the combined effect of
multiple interacting risk factors may be difficult to pre-
dict. Baseline imbalance could also introduce similar
biases for within-trial outcomes that are correlated with
baseline characteristics,22 although the problem may be
greater for models where the structure imposes/forma-
lizes relationships between end-of-trial characteristics
and outcome. Baseline imbalance will decrease with
increasing sample size,23 and its impact will depend on
the correlation between baseline variables and out-
come.22 It may have a greater effect on posttreatment
endpoints22 or absolute differences in event rates, life
years, QALYs, or costs compared with relative effects
(e.g., hazard ratios) or changes in intermediate endpoints
(e.g., change in blood pressure).
Adjusting for baseline covariates can also increase
precision.22,24–26 However, it is essential to ensure that
analyses are adjusted only for data observed before ran-
domization, rather than risk factors that may have been
affected by an intervention.
Given the matrix of predicted outcomes for each para-
meter set with each patient, it is possible to estimate
regression models that adjust for baseline covariates
using several convenient Stata commands (e.g., mim,
micombine, and mi estimate) that apply Rubin’s
rule to regression functions.
Methods
Case Study
AFORRD (ISRCTN: 76737502) was a 1-year factorial
double-blind RCT in which 800 patients with type 2
diabetes and no history of cardiovascular events were
randomized to 20 mg atorvastatin or placebo and, simul-
taneously, to omega-3 EE90 or placebo.11,27 General
practices were also cluster-randomized to receive a
paper-based behavioral intervention intended to increase
compliance with study medication or to standard care.27
Since high-risk patients in both arms were given addi-
tional atorvastatin after week 16,11 we extrapolated 16-
week clinical outcomes for 30 years and focus here on a
simple comparison of total undiscounted life expectancy
between atorvastatin and no atorvastatin, with no
adjustment for clustering. A 30-year time horizon was
chosen to cover the life expectancy of the average trial
participant (mean age, 64 years) while minimizing simu-
lation time. We assumed that all risk factors other than
age and event history would remain constant at the val-
ues observed at the end of the 16-week trial period.ii For
simplicity, we used a complete-case analysis, including
only the 732 patients with complete 16-week clinical
data. Mean imputation was used for the 36 patients with
missing baseline EQ-5D utility. Smoking status was
assumed to be the same as at baseline for 3 patients with
missing data on smoking status at week 16. All other 16-
week data were either fully observed (if the patient
attended the 16-week visit) or completely missing. A full
economic evaluation reporting sensitivity analyses will
be reported separately.
We predicted life expectancy for each individual parti-
cipating in AFORRD based on their 16-week risk factor
data using an adapted version of the UKPDS-OM2 that
saved the outputs required for our regression analyses.
The UKPDS-OM2 is a second-generation lifetime
individual-patient state transition model for people with
type 2 diabetes mellitus.2,28 It was constructed using IPD
from up to 89,760 patient years of follow-up in the
UKPDS. UKPDS-OM2 simulates the occurrence of
death and 8 diabetes-related complications (myocardial
infarction, ischemic heart disease, stroke, heart failure,
amputation, renal failure, diabetic foot ulcer, and blind-
ness in 1 eye) to estimate life expectancy, QALYs, and
costs. It is based on an integrated system of parametric
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equations that predict the annual probability of death
and complications; all model parameters have been pub-
lished and internally validated previously.2
Parameter uncertainty around these risk equations is
captured using 5000 sets of correlated risk equation coef-
ficients: the 15 regression equations predicting diabetic
events and mortality were jointly estimated on
each bootstrap sample drawn, with replacement, from
UKPDS trial population to allow for correlations
between coefficients across all 15 regression models.
Monte Carlo methods are used to randomly simulate a
possible medical history for each patient in each ‘‘loop’’
of the model.2 The likelihood of events for each patient
is based on the following risk factors: patient demo-
graphics, smoking, diabetes duration, body mass index,
high- and low-density lipoprotein (HDL, LDL), systolic
blood pressure, glycated hemoglobin (HbA1c), heart rate,
white blood cell count, hemoglobin, estimated glomeru-
lar filtration rate, albuminuria, and event history.
Different interventions can be evaluated through their
impact on the time paths of these risk factors (e.g.,
HbA1c) for a population of real or hypothetical individu-
als, which in turn will alter the probability of clinical
events occurring.
The model therefore has a 3-level simulation, predict-
ing L loops comprising lifetime outcomes for each of P
patients for each of B sets of bootstrapped model para-
meters. Each loop comprises a single lifetime disease tra-
jectory, showing when cardiovascular events and death
occur for 1 specific individual in the sample. This is esti-
mated by comparing random numbers against the
annual probability of events and death. These annual
probabilities are predicted by applying risk factor values
for patient P to a set of risk equations. Due to the ran-
dom or Monte Carlo element in their calculation, each
loop will return a different value, and so the results of
multiple loops are averaged to derive the expected value.
Uncertainty concerning the risk equation parameters is
dealt with by reestimating L loops for each patient using
B sets of risk equation parameters bootstrapped from
the UKPDS population.
In the case study, we extrapolated end-of-trial data
for each of the AFORRD trial participants and com-
pared the extrapolated outcomes between the 2 groups
as randomized.15 Extrapolating data for individual
patients is especially useful for evaluations based on a
single study as it makes few assumptions, preserves the
correlations between all clinical variables, and takes
account of uncertainty around treatment effects and the
variability between trial participants at baseline and over
the randomized trial period. However, this approach
means that any imbalance in baseline characteristics
between randomized groups is propagated into the extra-
polated estimates. Using this approach, the treatment
effect observed in the trial is not parameterized, and
uncertainty around treatment effects must be captured
statistically based on the variability between patients in
each group.
IPD from RCTs can also be extrapolated using
UKPDS-OM2 in several alternative ways. First, some
researchers have parametrically simulated data for
hypothetical patients based on the mean and standard
deviation (SD) for each clinical parameter.29,30 This
approach may be the only option when IPD are not
available but requires distributional assumptions and
makes it difficult to allow for correlations between differ-
ent patient characteristics (e.g., LDL and blood pres-
sure), particularly between continuous and dichotomous
variables. Second, other studies have extrapolated IPD
for 1 arm of the trial, with and without the addition of a
treatment effect equal to the difference between the 2
arms of the study.31 Providing treatment effects are addi-
tive, this approach will not be biased by baseline imbal-
ance and may be useful when it is necessary to compare
against comparators not included in the trial but means
that additional methods are required to allow for uncer-
tainty around treatment effects and account for correla-
tions between the treatment effects for different risk
factors. Using these approaches, parameter uncertainty
around treatment effects must be considered separately
(e.g., using PSA).
Analytical Methods for the Simulation Study
We conducted a simulation study to do the following:
1) Compare methods for combining sampling and
parameter uncertainty with respect to point esti-
mates, SEs, and coverage. We hypothesized that
95% CIs that include only parameter uncertainty
will be too narrow and have \95% coverage and
that methods combining parameter uncertainty and
sampling uncertainty would have wider 95% CIs
and 95% coverage.
2) Evaluate the impact of adjusting for baseline imbal-
ance in baseline risk factors in terms of point esti-
mates, SEs, and coverage. We hypothesized that this
would reduce SEs and alter point estimates by
removing the bias resulting from baseline imbalance.
3) Evaluate the impact of varying the number of loops
and assess whether the standard practice of running
large numbers of inner loops to minimize MCE is
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appropriate when IPD from an RCT are extrapo-
lated using PLS in a way analogous to multiple
imputation.
The protocol is given in Appendix 2. We used UKPDS-
OM2 to extrapolate the AFORRD trial for 30 years
using 1, 2000, and 1 million loops and estimated point
estimates and 95% CIs using 6 methods (Tables 2 and
3).
The long-run average against which other results were
compared comprised the mean difference in life expec-
tancy from a model run extrapolating the original
AFORRD sample (without bootstrapping) using 20,000
loops and all 5000 sets of bootstrapped model para-
meters, which was more than sufficient to give stable
results with a feasible simulation time. To calculate cov-
erage, we repeated analyses 1000 times and calculated
the proportion of 95% CIs that contained the long-run
average. The long-run average was adjusted for the same
covariates as the analyses against which it was com-
pared. We also calculated the empirical SE as the SD
across the 1000 estimates of mean difference in life
expectancy.
The analyses were intended to reflect the way that
researchers would extrapolate and analyze data from a
16-week RCT. Each run used a different set of 800 boot-
straps for UKPDS-OM2 parameters, and each model
run using 1 loop or 2000 loops also extrapolated out-
comes for a different bootstrap sample of patients drawn
with replacement from the AFORRD sample. The runs
therefore differed from another with respect to para-
meter uncertainty (bootstraps of model parameters),
sampling uncertainty (bootstrap samples of AFORRD
participants), and MCE (loops). All model analyses used
800 bootstraps, which is sufficient to estimate SEs to
610% accuracy based on the methods of O’Hagan
et al.17 and was found to give stable results (Appendix 3,
Figure A1). Each run therefore used 16% of the avail-
able 5000 bootstraps. Although methods have been
developed to calculate the optimal number of loops and
eliminate the systematic overestimation of SEs due to
MCE in some PLS models,17 these cannot be applied
easily in this setting since we have a 3-level simulation
(with L loops for each of B bootstraps of P patients).
We therefore compared SEs between model runs using
different numbers of loops and found that SEs differ
very little between 1000 loops and 1 million loops; 1000
runs of 2000 loops and 1 run of 1 million loops were
therefore chosen to keep the computation time feasible
(Table 3).
Results of the model-based analyses were analyzed
using 6 methods (Table 2), which are described in more
detail in Appendix 1 with code supplied in Appendix 4.
Coverage was not calculated for the run of 1 million
loops, since a single UKPDS-OM2 run took 4 weeks to
simulate, or for analysis 5, which took 2.5 hours to ana-
lyze per run. The mean and SE around the difference in
life expectancy were averaged across all replications. All
analyses were conducted in Stata version 14 (StataCorp
LLC, College Station, TX).
Financial support for the AFORRD trial was pro-
vided by a grant from Pfizer, although this methodologi-
cal work received no funding.
Results
Taking percentiles across the bootstraps (analysis 1, the
standard UKPDS-OM2 output) for the analysis using
2000 loops suggested that the atorvastatin arm of
AFORRD accrued 0.55 (95% CI, 0.42–0.69; P \ 0.001)
more life years than the placebo arm (Figure 1, Table 4).
However, this 95% CI includes only parameter uncer-
tainty around risk equations and ignores sampling uncer-
tainty of patient characteristics and treatment effects
within the AFORRD trial sample. The SEs from analy-
sis 1 were only 16% of the empirical SE. Consequently,
the coverage of the 95% CI for analysis 1 was 25%.
By contrast, the analyses combining parameter and
sampling uncertainty without adjusting for covariates
(analyses 2, 3, 4a, 5) estimated much wider 95% CIs (mean
difference: 0.55; 95% CI, –0.31 to 1.40). These analyses
did not find statins to significantly increase life expectancy
(P = 0.21) because of uncertainty around UKPDS-OM
model parameters and the noise introduced by variability
in life expectancy unrelated to statins. Sampling uncer-
tainty between patients in the AFORRD sample (including
heterogeneity and uncertainty around treatment effects)
accounted for 97.5% of the variance, and only 2.5% of the
variance was due to uncertainty around UKPDS-OM2
model parameters. (Formulae used to estimate these per-
centages are given in the ‘‘Analysis 2: Analytical Formulae
for Rubin’s Rule’’ section of Appendix 1.) Differences
between SEs calculated in analyses 2, 3, 4a, and 5 were
negligible, confirming the equivalence of Rubin’s rule ana-
lytically and summing variances (Appendix 1) and suggest-
ing that the parametric assumptions within analyses 2 to 4
have a minimal impact on the results. Across the 1000
runs, there was only a weak correlation between the
between-bootstrap variance and the within-bootstrap var-
iance (correlation coefficient: –0.11).
Adjusting for baseline levels of all UKPDS-OM2
input parameters within Rubin’s rule regression (analysis
4b) slightly reduced the mean difference in life
466 Medical Decision Making 40(4)
Table 2 Summary of the Analyses Conducteda
Analysis Description




95% CIs were calculated as the 2.5th and
97.5th percentiles across the mean
difference in life expectancy estimated for
the 800 sets of UKPDS-OM2 risk
equation parameters. This mirrors the
default method for calculating 95% CI
within the UKPDS-OM2.28
Parameter uncertainty only (excludes
sampling uncertainty and
heterogeneity). Does not adjust for
baseline imbalance.
2) Analytical formulas for
Rubin’s rule
Formulas adapted from Rubin’s rule were
used to combine parameter uncertainty
and sampling uncertainty in a way that
can easily be implemented without
specialist statistical software but which




Does not adjust for baseline
imbalance.
3) Summing within- and
between-bootstrap variance
The within-bootstrap variance (reflecting
sampling uncertainty) and the between-
bootstrap variance (reflecting parameter
uncertainty) were added together to give
an overall estimate of variance.
Parameter uncertainty, sampling
uncertainty, and heterogeneity.
Does not adjust for baseline
imbalance.
4a) Rubin’s rule regression
with no covariates
The mim Stata command37 was used to
implement Rubin’s rule in a regression
framework. This is broadly equivalent to
analysis 2 but makes the standard
assumptions of linear regression,
including assuming homoscedasticity,
whereas analysis 2 allowed variances to
differ between the atorvastatin and
placebo groups. This analysis included




Does not adjust for baseline
imbalance.





Variant on analysis 4a that adjusts for
nonwhite ethnicity, gender, age, duration
of diabetes, BMI, history of atrial
fibrillation, smoking, HDL cholesterol,
LDL cholesterol, blood pressure, and
HbA1c
b within a linear regression model
implementing Rubin’s rule using the mim
command.
Parameter uncertainty and sampling
uncertainty. Adjusts for baseline
imbalance (thereby excluding most
heterogeneity): controls for
different baseline risk factors in an
attempt to eliminate the bias
associated with baseline imbalance
and estimate 95% CIs that include
parameter uncertainty and
sampling uncertainty that is not
explained by the observed
covariates.
5) SD across bootstraps from
UKPDS and trial
Combines parameter uncertainty and
sampling uncertainty nonparametrically
by bootstrapping from the AFORRD
sample 1000 times within each of the 800
UKPDS bootstraps and calculating 95%
CI as the 2.5th and 97.5th percentiles
across the resulting 800,000 estimates.
Parameter uncertainty, sampling
uncertainty and heterogeneity.
Does not adjust for baseline
imbalance.
AFORRD, Atorvastatin in a Factorial design with Omega-3 fatty acids on cardiovascular Risk Reduction in patients with Type 2 Diabetes
study; BMI, body mass index; CI, confidence interval; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; SD, standard deviation; UKPDS-OM2, United Kingdom Prospective Diabetes Study Outcomes Model version 2.
aSee Appendix 1 for full details of the assumptions, methods, and formulas in each analysis.
bWe controlled for prerandomization values of all risk factors that were considered in the UKPDS-OM2 and varied between AFORRD
participants. Inclusion criteria meant that no trial participants had a history of cardiovascular events. We assumed that no patients had
albuminuria or peripheral vascular disease and set heart rate, white blood cell count, hemoglobin, and glomerular filtration rate to the mean
values observed in the Lipids in Diabetes study2 for all patients, since these data were not collected in AFORRD.
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expectancy by eliminating the bias introduced by imbal-
ance between groups. Minimizing the impact of hetero-
geneity by adjusting for baseline covariates also reduced
the SE by 77% and suggested that statin significantly
increased life expectancy (P \ 0.0001). However, the
coefficient for statin treatment varied little across the
1000 runs compared with analyses 2 to 4a (empirical SE:
0.075), such that coverage increased to 99.8%, despite
the reduction in estimated SE to 0.103.
Further analyses suggested that reducing the number
of baseline variables included in the regression gave SEs
and coverage that were in between those of analyses 4a
and 4b (Appendix 3, Table A5 and Figure A2).
Adjusting for age (the risk factor most strongly corre-
lated with life expectancy (Appendix 3, Table A6) gave
low SE, high coverage, and a point estimate markedly
smaller than with all covariates, while controlling for
LDL (the factor that was most imbalanced between
treatment arms, P = 0.069) had 96% coverage but a
high SE similar to that with no covariates.
Results with 1 million loops were very similar to those
with 2000 loops for analyses 2 to 4a (Appendix 3, Table
A5), confirming that 2000 loops were sufficient to mini-
mize MCE. However, SEs with 2000 loops were 15%
larger than with 1 million loops for analysis 1, 4.9% larger
for analysis 4b, but only 0.1% larger for analyses 2 to 4a.
SEs were markedly larger when only 1 loop was run
per bootstrap and no analysis observed a statistically sig-
nificant difference between groups (Table 4). With 1
loop, MCE accounted for 99% of the variance in analy-
ses 1 and 4b and 83% of the variance in analyses 2 to 4a,
and coverage was 99.7% for all analyses.
Discussion
We built on existing taxonomies of uncertainty6–8 to elu-
cidate the specific issues that can arise when combining
observed IPD from an RCT with posttrial outcomes
extrapolated using PLS modeling. It is hoped that subdi-
viding ‘‘uncertainty’’ into distinct categories will help
researchers, readers, and reviewers to consider explicitly
the different sources of uncertainty within their analyses
and how each type of uncertainty should be represented
and combined.
Our simulation study demonstrated the importance of
including sampling uncertainty as well as parameter
uncertainty when calculating SEs around statistics esti-
mated on groups of individual trial participants extrapo-
lated using a PLS, where the uncertainty around the
treatment effect is captured in the patient sample.
Ignoring sampling uncertainty produces SEs that are too
small and have low coverage, particularly in a small/
medium-sized trial like AFORRD. Underestimating SEs
could lead to incorrect conclusions that differences are
statistically significant, misrepresentation of the uncer-
tainty around treatment adoption decisions, and/or
underestimation of the value of conducting further
research. However, parameter uncertainty would be suf-
ficient when estimating outcomes for a single real or
hypothetical individual with known risk factors (since
sampling uncertainty is zero in this case, where the speci-
fied individual represents the whole population of
interest).
We also highlighted the bias introduced by baseline
imbalance between randomized groups in the variables
Table 3 Summary of the Model Runs Conducteda
Analyses









Monte Carlo error Negligible Very low Large Negligible
Number times analysis
was replicated
1 1000 1000 1
Analyses conducted 1,b 2,b 3,b 4a,b 4b,b 5b 1, 2, 3, 4a, 4b, 5b 1, 2, 3, 4a, 4b, 5b Regression with/
without covariatesc
UKPDS, United Kingdom Prospective Diabetes Study.
a(1) Percentiles across bootstraps. (2) Analytical formulas for Rubin’s rule. (3) Summing within-and between-bootstrap variance. (4) Rubin’s rule
regression including (a) no covariates and (b) adjusting for baseline values of all UKPDS-OM2 (United Kingdom Prospective Diabetes Study
Outcomes Model version 2) parameters. (5) Standard deviation across bootstraps from UKPDS and trial.
bCoverage not calculated.
cThe long-run average was used to calculate coverage by estimating the proportion of the 1000 runs in which the 95% confidence interval
contained the long-run average controlling for the same set of baseline variables. The long-run average without adjusting for baseline covariates
was used to estimate coverage for those analyses that did not adjust for baseline imbalance (i.e., analyses 1, 2, 3, and 4a). The long-run average
adjusting for all baseline UKPDS-OM parameters was used to estimate coverage for analysis 4a.
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that are used to predict outcomes beyond the end of the
trial, even when there were no statistically significant dif-
ferences in baseline risk factors between groups
(Appendix 3, Table A4).11 To minimize this bias, it is
necessary to adjust for prerandomization characteristics
when calculating differences between randomized groups
extrapolated using PLS. This changed point estimates in
this small/medium-sized trial with a marked imbalance
in LDL. Similar biases could arise in any analysis esti-
mating absolute differences in posttreatment outcomes,22
event rates, life expectancy or lifetime costs, or QALYs
for cohorts of trial participants (even if results are not
extrapolated beyond trial end). By contrast, other end-
points (e.g., costs, relative risks, or change in LDL) may
be only weakly correlated with baseline data, such that
baseline imbalance introduces noise but little bias. This
suggests that researchers should consider adjusting for
more prerandomization variables than is currently stan-
dard practice in within-trial economic evaluations. It has
been suggested that trial analyses should adjust for all
variables where the correlation with outcome is .0.5,
regardless of imbalance or sample size.26
Controlling for baseline characteristics also substan-
tially reduced SEs by accounting for heterogeneity in
baseline UKPDS-OM risk factors that explain much of
the variability in life expectancy between patients. The
extent to which SEs are reduced by covariate adjustment
depends on the strength of the correlation between the
covariate and outcome.26 In AFORRD, all covariates
have some prognostic value (because they are built into
the UKPDS-OM), and the correlation between life
expectancy and age is 20.968 (Appendix 3, Table A6);
SEs therefore reduce substantially when we adjust for
age or all covariates. By contrast, the correlation between
baseline LDL and life expectancy is 0.026, and adjusting
for LDL therefore has minimal impact on SEs despite
the marked imbalance.
However, when we controlled for all UKPDS-OM2
risk factors, coverage was markedly higher than 95%,
and SEs were 36% larger than the empirical SE, suggest-
ing that this analysis may be inefficient. We are unclear
why this should be the case, although it may be because
the UKPDS-OM determines the strong link between
risk factors and life expectancy, and all of the determi-
nants of posttrial outcomes are known and accounted
for in a way that would not happen in a within-trial
analysis. The apparent stability in the means may be an
artifact of the simulation, as the UKPDS-OM only has
100 seed values and 5000 sets of UKPDS-OM model
parameters; reusing seeds and parameter sets may have
reduced variability between runs and increased cover-
age. Consequently, the empirical SE may not be the
‘‘true’’ SE in this case. Despite the high coverage, it may
be appropriate to control for all model risk factors to
ensure that analyses can be prespecified in analysis plans
and minimize the risk of baseline imbalance affecting
the point estimate, even if this means that the 95% CI
may be inappropriately wide.
The simulation study confirmed that MCE should be
minimized even when we extrapolate IPD in a way that
is analogous to multiple imputation: analyses using only
1 loop gave 95% CIs that were too wide and had 100%
coverage. The simulation time was 1 hour for 2000 loops
and 26 days for 1 million loops (Appendix 3, Table A6),
although the difference in SEs was small. There is a need
for more research to identify the optimal number of
bootstraps and loops in models using a 3-level simula-
tion (e.g., with B bootstraps and L loops for P patients).
Figure 1 Results of each analysis with 2000 loops.




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































There may be fundamental differences between the types
of uncertainty affecting trial- and model-based economic
evaluation. In particular, the outcomes for a 30-year RCT
may be subject to stochastic uncertainty and sampling
uncertainty, whereas our model-based analysis 4a included
sampling uncertainty and parameter uncertainty and was
subject to (but excluded) structural uncertainty. In our expe-
rience, trial-based economic evaluations tend to have wider
95% CIs and a lower probability of a treatment being cost-
effective than model-based economic evaluations, which
may reflect these fundamental differences between trials
and models and the fact that stochastic uncertainty within a
trial may often be larger than parameter uncertainty within
a model. However, that trend could also reflect types of
uncertainty that are not fully captured within models at
present or differences between the types of evidence inform-
ing model-based (meta-analyses or explanatory trials) v.
trial-based (pragmatic trials) economic evaluations.
The 4 methods that we developed for combining sam-
pling and parameter uncertainty could be used to ana-
lyze clinical and economic endpoints in other settings;
Stata code is provided in Appendix 4. If it is not neces-
sary to adjust for covariates, any of the methods could
be used and give virtually identical results. Rubin’s rule
regression naturally facilitates adjustment for covariates.
The bootstrapping approach could also be adapted to
adjust for covariates by estimating treatment effects
using regression rather than sample means. Although it
takes longer to run the bootstrapping analysis, this
approach avoids parametric assumptions, facilitates con-
struction of scatter-graphs and cost-effectiveness accept-
ability curves, and could accommodate more complex
analyses (e.g., Kaplan-Meier sample averaging). A sepa-
rate study will illustrate how the bootstrapping approach
can be readily extended to economic evaluations consid-
ering both costs and QALYs, allowing for correlations
between costs and QALYs. Although our analysis did
not adjust for clustering by general practitioner practice
to avoid overcomplicating the analysis, this could be
accounted for by extending analysis 5 to use a 2-stage
bootstrap32,33 or applying Rubin’s rule to the results of a
mixed model.
In our simulation study, we did not consider structural
uncertainty or uncertainty around missing data; future
work could explore whether the methods identified here
can be adapted to incorporate these types of uncertainty
(e.g., by summing 3 variances together). Sensitivity analy-
ses would still be required to evaluate generalizability,
methodological uncertainty, and aspects of structural
uncertainty that cannot easily be parameterized. We
extrapolated 1 trial using UKPDS-OM2, although we
anticipate that the results would also apply in other set-
tings. Although the trial was small and lasted only 16
weeks, these limitations do not affect the proof of metho-
dological concepts.
Our results suggest that sampling uncertainty and
adjustment for covariates should be incorporated into
analyses using models such as UKPDS-OM2 to extrapo-
late data for individual participants in each study arm.
Future research should explore methods for combining
uncertainty when using simulated patients or adding
sample treatment effects to 1 patient cohort.
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Notes
i. Within this article, we use the term confidence interval to
refer to measures of the uncertainty around mean values.
However, the same principles would apply to credible inter-
vals calculated in a Bayesian analysis or analyses given a
Bayesian interpretation.
ii. Inclusion criteria meant that no AFORRD participants
had a history of cardiovascular events. We assumed that
no patients had albuminuria or peripheral vascular disease
and set heart rate, white blood cell count, hemoglobin, and
glomerular filtration rate to the mean values y2 observed in
the Lipids in Diabetes stud for all patients.
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